

Additional file 1. Baseline microbiological therapy in patients with isolated pulmonary *Candida spp.* colonization (cohort 1).

	Antifungal therapy (n=102)	No antifungal therapy (n=220)	p-value
Antifungal drugs, n (%)			
Echinocandins	16 (15.7%)		
Fluconazole	19 (18.6%)		
Others ¹	4 (3.9%)		
Combined ²	1 (1%)		
None	63 (61.8%)		
Antibiotics, n (%)			
Aminoglycosides	2 (2%)	8 (3.6%)	0.113
Penicillin	21 (20.6%)	55 (25%)	0.402
Cephalosporins	25 (24.5%)	39 (17.7%)	0.177
Quinolones	31 (30.4%)	38 (17.3%)	0.009
Macrolides	1 (1%)	9 (4.1%)	0.179
Carbapenems	37 (36.3%)	64 (29.1%)	0.2
Glycopeptides	46 (45.1%)	58 (26.4%)	0.001
Linezolid	9 (8.8%)	6 (2.7%)	0.022
Daptomycin	1 (1%)	1 (0.5%)	0.534
Others ³	16 (15.7%)	19 (8.6%)	0.082

¹ Amphotericin B, Voriconazole.

² at least two different antifungal drugs.

³ Chloramphenicol, Cotrimoxazole, Doxycycline, Fosfomycin, Fusidic acid, Metronidazole, Quinupristin/Dalfopristin, Rifampicin, Tigecycline, Trimethoprim/Sulfamethoxazole.